Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Monopar Therapeutics

Ticker
MNPR
Sector
Industry
Report date
November 12, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight Monopar's clinical and regulatory progress with ALXN1840, organizational changes, and financial results for Q2 2026.

Recent developments:
  • Monopar named a new head of Medical Affairs in August 2026 as ALXN1840 advances toward FDA decision [N1].
  • The company reported a widened net loss in Q2 2026 and is conducting a rolling NDA submission for ALXN1840 in Wilson Disease [N2].
  • Monopar was among biotech stocks reaching 52-week highs in early August 2026, reflecting market interest [N3].
  • ALXN1840 received FDA Rare Pediatric Disease Designation for Wilson Disease treatment in June 2026 [N4].
  • The NDA filing for ALXN1840 is on track as of June 2026, with positive FDA alignment reported [N5].
  • Wall Street analysts have expressed significant interest in Monopar's potential, with coverage noting possible rallies [N6].
  • Morgan Stanley initiated coverage with an overweight recommendation in January 2026 [N7].
  • Monopar was noted among biotech stocks that more than doubled in 2025, indicating strong prior performance [N8].
Overview

Monopar Therapeutics is a clinical-stage biopharmaceutical company specializing in therapies for rare diseases, notably Wilson Disease. Its lead candidate, ALXN1840, has progressed through Phase 2 and Phase 3 clinical trials, demonstrating significant copper reduction and promising efficacy signals. The company has received FDA Rare Pediatric Disease Designation for ALXN1840 and is engaged in a rolling NDA submission process. Monopar maintains a strong cash position and liquidity, supporting its clinical development and regulatory efforts. The company has also made organizational changes, including appointing a new head of Medical Affairs to support its advancing pipeline.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing ALXN1840 for Wilson Disease, which has received FDA Rare Pediatric Disease Designation. The company is advancing a rolling NDA submission and reported a net loss of $6.2 million for Q3 2026 with no revenue. As of September 30, 2026, Monopar held $52.6 million in cash and had strong liquidity ratios, supporting ongoing clinical and regulatory activities [S1][S2][N1][N2][N4].

Scenarios for MNPR

Bull case model:

The bull case for Monopar centers on the advancement of ALXN1840 through regulatory milestones, including the rolling NDA submission for Wilson Disease and the potential for FDA approval supported by positive clinical trial data. The Rare Pediatric Disease Designation may provide incentives such as priority review and market exclusivity. Strong liquidity and organizational enhancements, such as the appointment of a new Medical Affairs head, support the company's operational capacity to navigate regulatory processes and prepare for potential commercialization.

Bear case model:

The bear case involves the inherent risks of clinical-stage biopharmaceutical development, including the possibility that ALXN1840 may not receive FDA approval or may face delays in the regulatory process. The company currently reports net losses and no revenue, indicating ongoing funding needs and financial risk. Market competition, regulatory uncertainties, and the challenges of commercializing a rare disease therapy also present risks to the company's business model and valuation.

Moat:

Monopar's moat is primarily based on its specialized focus on rare diseases and its development of ALXN1840, which has received FDA Rare Pediatric Disease Designation, a regulatory status that can facilitate expedited review and potential market exclusivity. The company's clinical data from Phase 2 and Phase 3 trials provide a scientific foundation that may differentiate its product candidate. However, as a clinical-stage company without approved products or revenue, its moat depends heavily on successful regulatory approval and commercialization of ALXN1840.

Risks overview
Risks summary
The primary risk for Monopar Therapeutics is the uncertainty inherent in clinical development and regulatory approval of ALXN1840, compounded by financial risks due to ongoing net losses and lack of revenue.
Risks details:

• Regulatory Approval Risk: ALXN1840 is subject to FDA review and approval processes that carry uncertainty and potential delays or denials.
• Financial Risk: The company is currently operating at a net loss with no revenue, relying on cash reserves and financing to fund operations.
• Clinical Development Risk: Clinical trial outcomes may not confirm efficacy or safety, impacting the potential for approval and commercialization.
• Market and Commercialization Risk: Even if approved, ALXN1840 may face challenges in market adoption, reimbursement, and competition.

FINAL FORECAST FOR MNPR

Final take one line
Monopar Therapeutics exhibits very high visibility through detailed clinical progress, regulatory engagement, and strong liquidity supporting its rare disease drug development.
Final take 12 to 24 month view

Business trends: Advancement of ALXN1840 through clinical trials and regulatory milestones, including FDA Rare Pediatric Disease Designation and rolling NDA submission.
Execution milestones: Completion of Phase 3 trial analyses, NDA submission progress, and organizational strengthening with new Medical Affairs leadership.
Key risks: Regulatory approval uncertainty, ongoing net losses requiring funding, clinical trial outcome risks, and market adoption challenges.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases, including Wilson Disease.
  • The company is advancing ALXN1840, a drug candidate for Wilson Disease, which has received Rare Pediatric Disease Designation from the FDA as of June 30, 2026.
  • Monopar is conducting a rolling NDA submission for ALXN1840 for Wilson Disease treatment, indicating ongoing regulatory engagement.
  • The company reported a net loss of $6,196,475 for the quarter ended September 30, 2026, with no revenue recognized during this period.
  • As of September 30, 2026, Monopar held $52.6 million in cash and cash equivalents and had current assets of approximately $129.9 million against current liabilities of about $2.98 million, resulting in a strong current ratio of 43.55 and a cash ratio of 17.65.
  • The company named a new head of Medical Affairs in August 2026, reflecting organizational developments aligned with clinical progress.
  • Monopar's Phase 3 FoCus trial for ALXN1840 in treating Wilson Disease has reported promising analyses as of April 2026.
  • The company has ongoing clinical trial data showing significant copper reduction in Phase 2 trials for ALXN1840 in Wilson Disease.
  • Monopar Therapeutics is not a shell company and files reports as a smaller reporting company under SEC rules.
  • The company issued pre-funded warrants in September 2025 classified as equity instruments according to ASC 815-40, as audited and disclosed in the 10-K/A filing.
  • The company had approximately 6.69 million shares outstanding as of March 17, 2026.
  • Monopar Therapeutics has received multiple buy and overweight recommendations from financial analysts and firms, indicating market interest and coverage.
  • The company’s latest SEC filings include a 10-K/A for fiscal year ended December 31, 2025, and a 10-Q for the quarter ended September 30, 2026, both filed timely and containing detailed financial and operational disclosures.
Sources
Sources - Context summary

Generated 2026-11-12

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-04-01 | 10-K/A
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-08-19 | www.nasdaq.com | MNPR Names New Medical Affairs Head As ALXN1840 Advances Toward FDA Decision | https://www.nasdaq.com/articles/mnpr-names-new-medical-affairs-head-alxn1840-advances-toward-fda-decision
  • N2 | 2026-08-12 | www.nasdaq.com | Monopar Q2 Net Loss Widens; Rolling NDA Submission For ALXN1840 In Wilson Disease Underway | https://www.nasdaq.com/articles/monopar-q2-net-loss-widens-rolling-nda-submission-alxn1840-wilson-disease-underway
  • N3 | 2026-08-07 | www.nasdaq.com | Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX | https://www.nasdaq.com/articles/biotech-stocks-52-week-highs-dcth-22-q2-results-anro-coag-mnpr-nrix
  • N4 | 2026-06-30 | www.nasdaq.com | Monopar Therapeutics Granted Rare Pediatric Disease Designation To ALXN1840 To Treat Wilson Disease | https://www.nasdaq.com/articles/monopar-therapeutics-granted-rare-pediatric-disease-designation-alxn1840-treat-wilson
  • N5 | 2026-06-24 | www.nasdaq.com | Top Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment | https://www.nasdaq.com/articles/top-biotech-gainers-bold-begins-anew-mnpr-nda-filing-track-galt-soars-fda-alignment
  • N6 | 2026-06-15 | www.nasdaq.com | Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade | https://www.nasdaq.com/articles/wall-street-analysts-believe-monopar-therapeutics-mnpr-could-rally-8892-heres-how-trade
  • N7 | 2026-01-10 | www.nasdaq.com | Morgan Stanley Initiates Coverage of Monopar Therapeutics (MNPR) with Overweight Recommendation | https://www.nasdaq.com/articles/morgan-stanley-initiates-coverage-monopar-therapeutics-mnpr-overweight-recommendation
  • N8 | 2025-12-22 | www.nasdaq.com | What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 | https://www.nasdaq.com/articles/what-awaits-these-4-biotech-stocks-more-doubled-2025
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine